These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 28807232)

  • 41. New strategies in the treatment of ovarian cancer: current clinical perspectives and future potential.
    Banerjee S; Kaye SB
    Clin Cancer Res; 2013 Mar; 19(5):961-8. PubMed ID: 23307860
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Lovastatin induces apoptosis of ovarian cancer cells and synergizes with doxorubicin: potential therapeutic relevance.
    Martirosyan A; Clendening JW; Goard CA; Penn LZ
    BMC Cancer; 2010 Mar; 10():103. PubMed ID: 20298590
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Dasatinib + Gefitinib, a non platinum-based combination with enhanced growth inhibitory, anti-migratory and anti-invasive potency against human ovarian cancer cells.
    Thibault B; Jean-Claude B
    J Ovarian Res; 2017 Apr; 10(1):31. PubMed ID: 28446239
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Targeted therapy of ovarian cancer including immune check point inhibitor.
    Kim JY; Cho CH; Song HS
    Korean J Intern Med; 2017 Sep; 32(5):798-804. PubMed ID: 28823141
    [TBL] [Abstract][Full Text] [Related]  

  • 45. PARP inhibitors in ovarian and other cancers.
    Plummer R
    Clin Adv Hematol Oncol; 2015 May; 13(5):285-7. PubMed ID: 26352770
    [No Abstract]   [Full Text] [Related]  

  • 46. Molecular prognostic markers in ovarian cancer: toward patient-tailored therapy.
    Crijns AP; Duiker EW; de Jong S; Willemse PH; van der Zee AG; de Vries EG
    Int J Gynecol Cancer; 2006; 16 Suppl 1():152-65. PubMed ID: 16515584
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Starving tumors: inhibition of glycolysis reduces viability of human endometrial and ovarian cancer cells and enhances antitumor efficacy of GnRH receptor-targeted therapies.
    Reutter M; Emons G; Gründker C
    Int J Gynecol Cancer; 2013 Jan; 23(1):34-40. PubMed ID: 23154267
    [TBL] [Abstract][Full Text] [Related]  

  • 48. At the crossroads of cancer stem cells and targeted therapy resistance.
    Wang A; Qu L; Wang L
    Cancer Lett; 2017 Jan; 385():87-96. PubMed ID: 27816488
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Innovations in the treatment of ovarian cancer. Analysis of the therapeutic development: from platinum to immunotherapy.].
    Angius G; Sepe P; Papa A; Tomao S; Tomao F
    Recenti Prog Med; 2017 Jun; 108(6):269-281. PubMed ID: 28631775
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Evolving Strategies for Therapeutically Targeting Cancer Stem Cells.
    Talukdar S; Emdad L; Das SK; Sarkar D; Fisher PB
    Adv Cancer Res; 2016; 131():159-91. PubMed ID: 27451127
    [TBL] [Abstract][Full Text] [Related]  

  • 51. MicroRNA-136 inhibits cancer stem cell activity and enhances the anti-tumor effect of paclitaxel against chemoresistant ovarian cancer cells by targeting Notch3.
    Jeong JY; Kang H; Kim TH; Kim G; Heo JH; Kwon AY; Kim S; Jung SG; An HJ
    Cancer Lett; 2017 Feb; 386():168-178. PubMed ID: 27887917
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Molecular methods for increasing the effectiveness of ovarian cancer treatment: a systematic review.
    Chilimoniuk Z; Rocka A; Stefaniak M; Tomczyk Ż; Jasielska F; Madras D; Filip A
    Future Oncol; 2022 Apr; 18(13):1627-1650. PubMed ID: 35129396
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Gene-expression signatures in ovarian cancer: Promise and challenges for patient stratification.
    Konecny GE; Winterhoff B; Wang C
    Gynecol Oncol; 2016 May; 141(2):379-385. PubMed ID: 26827964
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Biomarkers in Ovarian Cancer: Towards Personalized Medicine.
    López-Portugués C; Montes-Bayón M; Díez P
    Proteomes; 2024 Mar; 12(1):. PubMed ID: 38535506
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Ovarian cancer: emerging molecular-targeted therapies.
    Sourbier C
    Biologics; 2012; 6():147-54. PubMed ID: 22807625
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Editorial: Ovarian cancer-targeted medication: PARP inhibitors, anti-angiogenic drugs, immunotherapy, and more.
    Wang ZB; Liu D; Lei G; Liu ZQ; Wu N; Wang J
    Front Pharmacol; 2023; 14():1222209. PubMed ID: 37361211
    [No Abstract]   [Full Text] [Related]  

  • 57. New Strategies and In Vivo Monitoring Methods for Stem Cell-Based Anticancer Therapies.
    Wang P; Aguirre A
    Stem Cells Int; 2018; 2018():7315218. PubMed ID: 30581474
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Ensemble biomarkers for guiding anti-angiogenesis therapy for ovarian cancer using deep learning.
    Wang CW; Lee YC; Lin YJ; Chang CC; Sai AK; Wang CH; Chao TK
    Clin Transl Med; 2023 Jan; 13(1):e1162. PubMed ID: 36639829
    [No Abstract]   [Full Text] [Related]  

  • 59. Targeted therapy: ARIEL3 - broad benefit of PARP inhibitors in ovarian cancer.
    Killock D
    Nat Rev Clin Oncol; 2017 Dec; 14(12):713. PubMed ID: 28994419
    [No Abstract]   [Full Text] [Related]  

  • 60. Gene therapy for ovarian cancer: development of novel treatment strategies.
    Dorigo O; Berek JS
    Int J Gynecol Cancer; 1997 Jan; 7(1):1-13. PubMed ID: 12795798
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.